Healthcare Industry News: fluticasone furoate
News Release - February 8, 2017
GSK Consumer Healthcare Launches FLONASE(R) Sensimist(TM) Allergy Relief NationwideWARREN, N.J., Feb. 8, 2017 -- (Healthcare Sales & Marketing Network) -- GSK Consumer Healthcare today announced the nationwide launch of FLONASE® Sensimist™ Allergy Relief (fluticasone furoate, 27.5 mcg spray), a new over-the-counter (OTC) treatment for symptoms associated with seasonal and perennial allergies.
Taken once daily, directly in the nose, FLONASE Sensimist protects against allergies caused by triggers including pollen, mold, dust and pets. Unlike most OTC allergy pills, which act on histamine alone, FLONASE Sensimist helps block six key inflammatory substances.ii Further, FLONASE Sensimist has been found to be 40% stronger than a leading non-drowsy allergy pill.iii
"For the more than 50 million Americans who suffer from allergies, the burden is more than just a stuffy nose," said Dr. Clifford Bassett, Founder and Medical Director of Allergy & Asthma Care of New York. "Uncontrolled allergies have a measurable impact on quality of life, affecting children and adults. In my patient population, having a proactive treatment plan in place makes a big difference in managing their allergies."
Additional key features of FLONASE Sensimist's unique, ergonomic design include:
- Little or no drip
- Less invasive with the shortest nozzle
- Delivers consistent dosing each time
"GSK Consumer Healthcare has a strong heritage in discovering and developing respiratory products to meet patient needs worldwide," said Jennifer Nadelson, Senior Brand Manager, FLONASE. "With FLONASE Sensimist, we're proud to offer allergy sufferers an additional product option providing more complete symptom reliefi in a new, unique, user-friendly device."
FLONASE Sensimist is available online and at major retail stores nationwide. For more information, please visit www.flonase.com/products/sensimist.
About FLONASE® Sensimist™
FLONASE Sensimist (fluticasone furoate, 27.5 mcg spray) is an approved over-the-counter treatment for symptoms associated with seasonal and perennial allergic rhinitis including sneezing, runny nose, itchy nose, congestion, and itchy, watery eyes.*
About GSK Consumer Healthcare
GSK Consumer Healthcare is one of the world's largest consumer healthcare companies. Our purpose is to help more people around the world to do more, feel better and live longer with everyday healthcare products. We have a heritage that goes back over 160 years. We own some of the world's best loved healthcare brands, including Sensodyne®, Theraflu®, Excedrin®, Nicorette® and NicoDerm®CQ®, FLONASE®, and TUMS®. These brands are successful in over 100 countries around the world because they all show our passion for quality, guaranteed by science. They are inspired by the real wants and needs of the millions of people who walk into pharmacies, supermarkets, market stalls and go on-line all over the world every day, and choose us first.
Our goal is to build a global, growing business we call a Fast Moving Consumer Healthcare (FMCH) company, dedicated to everyday healthcare with all of the scientific expertise and quality guarantees that demands, working at the speed and with the genuine consumer understanding the modern world expects.
GlaxoSmithKline – one of the world's leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For company information visit: http://www.gsk.com.
i Vs. single-ingredient antihistamines which do not treat nasal congestion
ii FLONASE Sensimist Allergy Relief acts on multiple inflammatory substances (histamine, prostaglandins, cytokines, tryptases, chemokines and leukotrienes). The exact number and precise mechanism are unknown.
iii Total nasal symptoms vs single-ingredient fexofenadine 180mg.
* Indication for "itchy, watery eyes" for ages 12 years and older.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.